Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: A prospective, randomized, multicentre trial

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 4, 2007, Pages 711-717

  Torfoss, Dag ^a   Høiby, Arne E ^a,b   Tangen, Jon Magnus ^c   Holte, Harald ^a   Bø, Kåre ^d   Meyer, Peter ^e   Grøttum, Kjell ^f   Weyde, Kjetil ^g   Lauritzsen, Grete Fossum ^a   Sandstad, Berit ^a,h   Jacobsen, Anne Birgitte ^a   Olsen, Harald ^a   Kvaløy, Stein ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d Buskerud Central Hospital   (Norway)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f SØRLANDET HOSPITAL   (Norway)

^g INNLANDET HOSPITAL TRUST   (Norway)

^h Kreftforeningen   (Norway)

Author keywords

Antibiotics; Fever; Neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTAZIDIME; CISPLATIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NORWAY; OTOTOXICITY; OUTCOMES RESEARCH; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; FEVER; MIDDLE AGED; NEOPLASM; NEUTROPENIA; SAMPLE SIZE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; NORWAY; PENICILLIN G; PROSPECTIVE STUDIES; SAMPLE SIZE; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 34249992661     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm003     Document Type: Article

References (30)

1. NORM/NORM-VET 2005. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo, 2005. ISSN: 1502-2307.
2. Goossens H, Ferech M, Vander Stichele R et al. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005; 365: 579-87.
3. Vander Stichele RH, Elseviers MM, Ferech M et al. Hospital consumption of antibiotics in 15 European countries: Results of the ESAC retrospective data collection (1997-2002). J Antimicrob Chemother 2006; 58: 159-67.
4. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999; 96: 1152-6.
5. McGowan JE, Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5: 1033-48.
6. Owens RC, Jr, Rice L. Hospital-based strategies for combating resistance. Clin Inf Dis 2006; 42: S173-81.
7. Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother 1999; 11: 28-33.
8. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis 2004; 10: 514-7.
9. Hammerstrøm J, Jacobsen T. Bakteriemi ved granulocytopeni - mikrobiologi og empirisk antibiotikabehandling [in Norwegian]. Tidsskr Nor Lægeforen 1998; 118: 4370-5.
10. Tangen JM, Berentsen S, Dahl IM et al. Antibiotics in acute myelocytic leukemia. Rev Med Liban 2000; 12: 58-62.
11. Sigurdardottir K, Digranes A, Harthug S et al. A multi-centre prospective study of febrile neutropenia in Norway: Microbiological findings and antimicrobial susceptibility. Scand J Infect Dis 2005; 37: 455-64.
12. de Man P, Verhoeven BAN, Verbrugh HA et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000; 355: 973-8.
13. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V ed. Antibiotics in Laboratory Medicine, 4th Edition. Baltimore: Williams and Wilkins, 1996; 296-329.
14. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antimicrobial dosing of mice and men. Clin Infect Dis 1998; 26 1-12.
15. Paul M, Yahav D, Fraser A et al. Empirical antibiotic monotherapy for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57 176-89.
16. Gaya H, Klastersky J, Schimpff SC et al. Protocol for a cooperative trial of empirical antibiotic treatment and early granulocyte transfusions in febrile neutropenic patients. Eur J Cancer 1977; 13: 617-21.
17. Pizzo PA, Armstrong D, Bodey G et al. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect Dis 1990; 161: 397-401.
18. Feld R, Paesmans M, Freifeld AG et al. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis 2002; 35: 1463-8.
19. Klastersky J, Gaya H, Glauser MP et al. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978; 137: 14-29.
20. Zinner SH, Gaya H, Glauser MP et al. Combination of amikacin and carbencillin with or without cefazolin as empirical treatment of febrile neutropenic patients. J Clin Oncol 1983; 1: 597-603.
21. Klastersky J, Glauser MP, Schimpff SC et al. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986; 29: 263-70.
22. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692-8.
23. Rozdzinski E, Kern WV, Reichle A et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother 1993; 31: 585-98.
24. EORTC International Antimicrobial Therapy Cooperative Group. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-93.
25. Klastersky J. Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer 1993; 29A: S6-S10.
26. Bodey GP, Middleman E, Umsawadi T et al. Infections in cancer patients. Results with gentamicin sulphate therapy. Cancer 1972; 29: 1697-1701.
27. Bodey GP, Rodriguez V. Advances in the management of Pseudomonas aeruginosa infections in cancer patients. Eur J Cancer 1973; 9: 435-41.
28. Schimpff S, Satterlee W, Young VM et al. Empiric therapy with carbencillin and gentamicin for febrile patients with cancer and granulo-cytopenia. N Engl J Med 1971; 284: 1061-5.
29. Dale DC, Reynolds HY, Pennington JE et al. Experimental Pseudomonas pneumonia in leukopenic dogs: Comparison of therapy with antibiotics and granulocyte transfusions. Blood 1976; 47: 869-76.
30. Hughes WT, Armstrong D, Bodey GP et al. IDSA guidelines. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.